NOVO NORDISK TAKES ON THE WEIGHT OF THE WORLD.

The article focuses on the mission of pharmaceutical company Novo Nordisk to prevent patients from becoming obese and its efforts in developing obesity drugs. It highlights the company's drug research and development on diabetes and obesity that led to the semaglutide Type 2 diabetes drug Ozempic and Wegovy for treatment of obesity, which were both approved by the U.S. Food and Drug Administration (FDA).